I really sit down and look at what’s out there right now in this space and there is huge opportunity for NYR to become a 120 million market cap leading into phase 2 like AGN. NYR will be doing TBI and stroke plus as a drug molecule and not a peptide can be made in a variety of formulations from tablets to nasal sprays and puffers. Company is currently at a 9 million market cap and with rebates coming in will be fully funded to get the drug to phase 2. The main thing right now is the safety results coming over the next few weeks plus Walter Reed success of any sort will provide the company with huge opportunities for non dilutive funding for phase 2.
So it’s all about safety. Efficacy and comparing this to different drugs, you can’t because nothing is approved out there for these conditions via the FDA. So the potential upside is exponential on safety success because the drug works
- Forums
- ASX - By Stock
- NYR
- Ann: Brain Injury Program GLP Studies Further Update
NYR
nyrada inc.
Add to My Watchlist
2.94%
!
33.0¢

Ann: Brain Injury Program GLP Studies Further Update, page-36
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
33.0¢ |
Change
-0.010(2.94%) |
Mkt cap ! $69.60M |
Open | High | Low | Value | Volume |
34.0¢ | 34.3¢ | 32.5¢ | $195.9K | 589.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 14970 | 33.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
33.5¢ | 20100 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 14970 | 0.330 |
3 | 41398 | 0.325 |
2 | 77000 | 0.320 |
2 | 96590 | 0.315 |
8 | 104200 | 0.310 |
Price($) | Vol. | No. |
---|---|---|
0.335 | 20100 | 1 |
0.340 | 76361 | 2 |
0.345 | 56182 | 2 |
0.350 | 22442 | 3 |
0.355 | 24064 | 1 |
Last trade - 15.29pm 25/07/2025 (20 minute delay) ? |
Featured News
NYR (ASX) Chart |
The Watchlist
P.HOTC
HotCopper
Frazer Bourchier, Director, President and CEO
Frazer Bourchier
Director, President and CEO
SPONSORED BY The Market Online